Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Stocks · News reference
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate
Atea Pharmaceuticals shares are trading lower. The company announced topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.